Fuan Pharmaceutical (Group) Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	14.7yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

May 02

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Apr 03

CEO

Fuan Pharmaceutical (Group) has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xue Song Yu	Deputy GM	14.7yrs	CN¥558.90k	0.011% CN¥ 529.1k
Jing Feng	Deputy General Manager	14.7yrs	CN¥561.90k	0.023% CN¥ 1.1m
Rong Chuan Hong	Deputy General Manager	14.7yrs	CN¥496.60k	0.016% CN¥ 774.8k
Yong Ping Sun	Deputy General Manager	3.8yrs	CN¥565.20k	0.025% CN¥ 1.2m
Tao Huang	Deputy GM & Director	11.4yrs	CN¥670.70k	0.74% CN¥ 36.7m
Xionghui Wu	Deputy General Manager	2.4yrs	CN¥561.50k	0.000080% CN¥ 4.0k
Qin Tang	Secretary of the Board of Directors & Director	14.7yrs	CN¥561.90k	0.024% CN¥ 1.2m

14.7yrs

Average Tenure

53yo

Average Age

Experienced Management: 300194's management team is seasoned and experienced (14.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xue Song Yu	Deputy GM	14.7yrs	CN¥558.90k	0.011% CN¥ 529.1k
Tao Huang	Deputy GM & Director	11.4yrs	CN¥670.70k	0.74% CN¥ 36.7m
Qin Tang	Secretary of the Board of Directors & Director	14.7yrs	CN¥561.90k	0.024% CN¥ 1.2m
Lu Wang	Vice Chairman	2.4yrs	CN¥687.90k	no data
Tianxiang Wang	Chairman	14.7yrs	CN¥875.80k	24% CN¥ 1.2b
Zi Wei Guo	Supervisor	5.9yrs	CN¥197.50k	no data
Wei Wang	Director	5.9yrs	CN¥614.00k	no data
Wen Shuo Xiong	Independent Director	5.4yrs	CN¥60.00k	no data
Shu Zhu	Independent Director	5.4yrs	CN¥60.00k	no data
Geng Chen	Independent Director	2.4yrs	CN¥55.00k	no data
Yong Yang	Chairman of the Supervisory Board	1.8yrs	no data	no data

5.9yrs

Average Tenure

53yo

Average Age

Experienced Board: 300194's board of directors are considered experienced (5.9 years average tenure).

Fuan Pharmaceutical (Group) Management

Management criteria checks 2/4

Key information

Recent management updates

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Fuan Pharmaceutical (Group)'s (SZSE:300194) Shareholders May Want To Dig Deeper Than Statutory Profit

Fuan Pharmaceutical (Group) Co., Ltd. Proposes Final Cash Dividend for 2023

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2023)

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment deteriorates as stock falls 17%

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 3Q 2022)

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 2Q 2022)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 12 May 2023

First quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in 1Q 2022)

Now 22% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.05 in 2Q 2020)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Implementation of Profit Distribution Plan for A Shares for the Year 2020, Payable on 14 May 2021

First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.06 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥0.25 in FY 2019)

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.18

New 90-day low: CN¥4.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.42

New 90-day high - CN¥6.57

Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥6.27

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age